Larimar Therapeutics, Inc.
LRMR
$3.58
-$0.31-7.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.85M | 4.67M | 4.52M | 4.74M | 4.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.02M | 49.50M | 27.79M | 31.19M | 31.29M |
| Operating Income | -64.02M | -49.50M | -27.79M | -31.19M | -31.29M |
| Income Before Tax | -62.50M | -47.71M | -26.18M | -29.28M | -28.82M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -62.50M | -47.71M | -26.18M | -29.28M | -28.82M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.50M | -47.71M | -26.18M | -29.28M | -28.82M |
| EBIT | -64.02M | -49.50M | -27.79M | -31.19M | -31.29M |
| EBITDA | -63.93M | -49.41M | -27.71M | -31.10M | -31.22M |
| EPS Basic | -0.73 | -0.61 | -0.41 | -0.46 | -0.45 |
| Normalized Basic EPS | -0.46 | -0.38 | -0.26 | -0.29 | -0.28 |
| EPS Diluted | -0.73 | -0.61 | -0.41 | -0.46 | -0.45 |
| Normalized Diluted EPS | -0.46 | -0.38 | -0.26 | -0.29 | -0.28 |
| Average Basic Shares Outstanding | 85.18M | 78.32M | 64.03M | 63.96M | 63.81M |
| Average Diluted Shares Outstanding | 85.18M | 78.32M | 64.03M | 63.96M | 63.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |